XML 56 R45.htm IDEA: XBRL DOCUMENT
v3.23.1

Moderna Collaboration and License Agreement - Performance obligations (Details) $ in Thousands | Mar. 31, 2023 USD ($)
--- | ---
Performance obligations: |
Research and development | $ 61,376
Option rights | 45,000
Total performance obligations | $ 106,376

X
- Definition Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue. + References No definition available. + Details
Name: | carm_RevenueRemainingPerformanceObligationOptionRightsAmount
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue. + References No definition available. + Details
Name: | carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_RevenuePerformanceObligationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant